262 related articles for article (PubMed ID: 22049782)
1. Plenty of green in gray market. There's more at issue than just inflated prices for drugs in short supply.
May D
Mod Healthc; 2011 Oct; 41(42):25. PubMed ID: 22049782
[No Abstract] [Full Text] [Related]
2. Shades of gray. Secondary drug distributors raise questions.
Lee J
Mod Healthc; 2011 Oct; 41(41):10, 12. PubMed ID: 22111494
[No Abstract] [Full Text] [Related]
3. Prescription drug prices in the US.
Med Lett Drugs Ther; 2017 May; 59(1521):81-83. PubMed ID: 28520697
[No Abstract] [Full Text] [Related]
4. Laws fail to slow gray market. Concerns raised over secondary drug distributors.
Lee J
Mod Healthc; 2011 Oct; 41(40):14. PubMed ID: 22049854
[No Abstract] [Full Text] [Related]
5. An Incomplete Prescription: President Trump's Plan to Address High Drug Prices.
Sarpatwari A; Avorn J; Kesselheim AS
JAMA; 2018 Jun; 319(23):2373-2374. PubMed ID: 29800027
[No Abstract] [Full Text] [Related]
6. Captive markets.
Mettner J
Minn Med; 2008 Nov; 91(11):12-3. PubMed ID: 19108536
[No Abstract] [Full Text] [Related]
7. How insurers' bargaining power affects drug prices in Medicare Part D.
Natl Bur Econ Res Bull Aging Health; 2009; (4):1-2. PubMed ID: 20355274
[No Abstract] [Full Text] [Related]
8. Running short.
Mettner J
Minn Med; 2011 Oct; 94(10):8-10. PubMed ID: 23256277
[No Abstract] [Full Text] [Related]
9. Prices gone wild: grey market 'scalpers' scoring windfall in American drug market.
Woodward C
CMAJ; 2012 Feb; 184(2):E119-20. PubMed ID: 22231687
[No Abstract] [Full Text] [Related]
10. Prescription-price sticker shock: Will federal lawmakers intervene?
Johnson SR
Mod Healthc; 2015 Oct; 45(43):8-9. PubMed ID: 26619614
[No Abstract] [Full Text] [Related]
11. Prescription-drug prices.
Frank RG
N Engl J Med; 2004 Sep; 351(14):1375-7. PubMed ID: 15459294
[No Abstract] [Full Text] [Related]
12. Copayment coupons undermine formularies.
Manag Care; 2011 Dec; 20(12):63. PubMed ID: 22259878
[No Abstract] [Full Text] [Related]
13. Going over the patent cliff.
Schommer JC
Minn Med; 2011 Oct; 94(10):42-3. PubMed ID: 23256283
[No Abstract] [Full Text] [Related]
14. Drug Imports: The New Idea That's Kind of Old.
Kirkner RM
Manag Care; 2016 May; 25(5):12-3. PubMed ID: 27351059
[No Abstract] [Full Text] [Related]
15. America's other drug problem: how the drug industry distorts medicine and politics.
Relman AS; Angell M
New Repub; 2002 Dec; 227(25):27-41. PubMed ID: 12561803
[No Abstract] [Full Text] [Related]
16. RX for nosebleed prices.
Greenwald J
Time; 2001 May; 157(20):42-3. PubMed ID: 11383109
[No Abstract] [Full Text] [Related]
17. State Initiatives to Control Medication Costs--Can Transparency Legislation Help?
Sarpatwari A; Avorn J; Kesselheim AS
N Engl J Med; 2016 Jun; 374(24):2301-4. PubMed ID: 27305189
[No Abstract] [Full Text] [Related]
18. There's still gold in them thar pills.
O'Reilly B
Fortune; 2001 Jul; 144(2):58-62, 66-8, 70. PubMed ID: 11471355
[No Abstract] [Full Text] [Related]
19. Trends in Prescription Drug Launch Prices, 2008-2021.
Rome BN; Egilman AC; Kesselheim AS
JAMA; 2022 Jun; 327(21):2145-2147. PubMed ID: 35670795
[TBL] [Abstract][Full Text] [Related]
20. Recent Trends in Prescription Drug Launch Prices.
Ybarra M; Weissman R
JAMA; 2022 Oct; 328(13):1352. PubMed ID: 36194225
[No Abstract] [Full Text] [Related]
[Next] [New Search]
